Seros Financial LLC Invests $159,000 in Omeros Co. (NASDAQ:OMER)

Seros Financial LLC bought a new position in shares of Omeros Co. (NASDAQ:OMER) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,115 shares of the biopharmaceutical company’s stock, valued at approximately $159,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OMER. BNP Paribas Financial Markets lifted its holdings in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares during the period. MML Investors Services LLC lifted its holdings in Omeros by 19.2% in the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 3,000 shares during the period. SPC Financial Inc. purchased a new stake in Omeros in the 3rd quarter worth approximately $77,000. SG Americas Securities LLC acquired a new stake in shares of Omeros during the 3rd quarter worth approximately $80,000. Finally, AQR Capital Management LLC purchased a new position in shares of Omeros during the 2nd quarter valued at approximately $105,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OMER has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Friday, January 17th. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a report on Thursday, November 14th. D. Boral Capital reiterated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Thursday, January 16th. Finally, Rodman & Renshaw initiated coverage on Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Down 3.0 %

Shares of NASDAQ OMER opened at $9.01 on Friday. Omeros Co. has a twelve month low of $2.61 and a twelve month high of $13.60. The stock has a fifty day simple moving average of $9.65 and a 200-day simple moving average of $6.13.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.